BillionToOne is a precision diagnostics company dedicated to transforming healthcare through its proprietary Quantitative Counting Templates (QCTs™) technology. This innovative platform enables the direct measurement of disease-causing DNA fragments at the single base-pair level, significantly enhancing the accuracy and efficiency of molecular diagnostics. By quantifying these minute variations using cell-free DNA, BillionToOne aims to revolutionize prenatal screening, liquid biopsy, and other diagnostic applications. Key Features and Functionality: - UNITY Complete®: The first non-invasive prenatal test (NIPT) that utilizes cell-free DNA to assess fetal risk for recessive conditions and aneuploidies from a single maternal blood sample as early as nine weeks into pregnancy. - Northstar Select® and Northstar Response®: Comprehensive pan-cancer liquid biopsy tests designed to guide therapy selection and enable real-time treatment response monitoring, providing actionable insights for oncology care. Primary Value and User Solutions: BillionToOne's cutting-edge diagnostics offer healthcare providers and patients more accurate, efficient, and accessible testing options. By delivering precise measurements of genetic material, their products facilitate early detection and monitoring of genetic and cancer-related conditions. This empowers clinicians to make informed decisions, leading to improved patient outcomes and personalized treatment plans.